KeyBanc cuts STERIS stock price target on lower peer multiples By Investing.com

KeyBanc cut its price target on STERIS to $269 from $291 while keeping an Overweight rating, citing lower peer multiples rather than a deterioration in fundamentals. STERIS missed Q4 EPS at $2.83 vs. $2.85 expected, but beat revenue at $1.6 billion vs. $1.59 billion and guided for 6%-7% organic growth in fiscal 2027 with EPS ahead of Street estimates. The mixed quarter is modestly positive overall because guidance and capital allocation commentary offset the slight earnings miss.

Analysis

The setup looks like a classic quality-compounding name being de-rated by sector multiple compression rather than a fundamental inflection. That matters because the business can keep executing while the stock still underperforms if investors stay focused on current-period margin noise and ignore the medium-term earnings power embedded in sustained mid-single-digit organic growth plus operating leverage. The market is likely underappreciating how much of the valuation reset has already happened if the company is still compounding earnings ahead of consensus over the next 12-18 months.

Second-order, this is a read-through for med-tech and specialty healthcare suppliers with similar profiles: strong balance sheets, recurring demand, and pricing power in an otherwise cautious capex environment. If STERIS can hold guide despite macro volatility, that supports a broader “defensive growth” bid in adjacent names where investors have been overly punitive on near-term EPS misses. The main beneficiary is likely peer multiples in the space; the main loser is the bear case that assumes margin pressure is uniformly structural across healthcare infrastructure suppliers.

The key risk is not execution failure this quarter but a slower-than-expected rebound in hospital utilization, procedure volumes, or capital spending that keeps the multiple trapped for several months. In the shorter term, any follow-through selling on the revenue/EPS miss could be a dislocation rather than a thesis break, especially if buybacks or capital allocation announcements turn incremental free cash flow into per-share growth. Over a 6-12 month horizon, the catalyst that matters is whether management converts the guidance into visible margin expansion; if they do, the current valuation reset should prove too severe.

Consensus may be missing that guidance confidence itself is valuable in a market where many healthcare industrial names are being punished for uncertainty, not just earnings misses. The stock is less a call on near-term beats and more a bet that premium-quality cash generation deserves a stable-to-higher multiple once peer de-rating bottoms. If that multiple floor holds, the asymmetry favors owning weakness rather than chasing strength.

Key Decisions for Investors

• Go long STE on weakness over the next 1-3 weeks if post-earnings selling continues; target a 6-12 month hold with 15-20% upside from de-rated levels and a relatively contained downside if guidance holds.
• Use a call spread in STE (3-6 month tenor) to express the view that the stock re-rates as the market gains confidence in FY27 margin expansion; risk is limited premium outlay with convex upside if peers stabilize.
• Pair trade: long STE / short a lower-quality med-tech or healthcare equipment name with similar valuation sensitivity but weaker balance sheet execution; hold 3-6 months to isolate quality premium re-rating.
• Add STE to a defensive-growth basket alongside other high-quality healthcare compounders; expect better relative performance if macro volatility keeps investors favoring durable cash flow over cyclical growth.
• If STE reclaims its pre-guidance multiple band over the next 2-4 months, trim 25-50% rather than fully exit; the re-rating may be quicker than the earnings step-up, so capture the first leg of multiple normalization.